Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03623321 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
A Phase 3 study, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 595
- Enrollment target
NCT03623321 is a Phase 3 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 595 participants.
The verdict
NCT03623321, a Phase 3 study, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 595 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease exposed to open-label pimavanserin for up to 52 weeks.
Interventions
- DRUG Pimavanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 595 participants |
| Start Date | 2018-07-17 |
| Est. Completion | 2023-05-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03623321
The ClinicalTrials.gov registry entry for NCT03623321 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 595 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pimavanserin is the first listed.
NCT03623321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03623321 about?
NCT03623321 is a clinical study titled "Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease". The purpose of this study is to evaluate the long-term safety and tolerability of pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease exposed to open-label pimavanserin for up to 52 weeks.
What is the current status of trial NCT03623321?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 595 participants. The study started on 2018-07-17. Estimated completion is 2023-05-05.
What interventions are being tested in trial NCT03623321?
The interventions under investigation include: Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT03623321?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.